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Results: The optimal signature contained 28 genes. Therewas a
statistically significant correlation between actual versus pre-
dicted time to recurrence for blind data (rho = 0.975; p < 0.0001).
A prospective Kaplan–Meier plot was generated which showed
no significant difference to the actual Kaplan–Meier plot for this
dataset (p > 0.955).
Discussion: For the first time gene expression signatures have
been identified that predict actual time to event data rather than
placing patients into arbitrary risk groups. Coupled with the abil-
ity to derive prospective Kaplan–Meier plots, this tool has the
potential for assessing prognosis and determining treatment reg-
imens on a case by case basis.
doi:10.1016/j.ejcsup.2010.06.034
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Dynamic contrast-enhanced MRI (DCE-MRI) is a widely used
imaging modality for the management of breast cancer patients.
At present, there is little understanding of how imaging patterns
on DCE-MRI relate to the molecular pathways that drive tumour
growth.
To address this issue, we performed a retrospective study of 65
patients with primary breast cancer, for whom pre-treatment
DCE-MRI scans and formalin fixed paraffin embedded (FFPE) core
biopsies were available. We used pharmacokinetic modelling of
DCE-MRI to quantify the rate constant kep governing contrast
agent washout from the tumour extravascular extracellular
space. By computing the median kep over tumour volume an
overall tumour leakiness score was derived. We extracted RNA
from FFPE cores and measured gene expression using Affymetrix
Human Plus 2.0 arrays. Following normalization and pre-process-
ing, we used permutation tests to determine which genes were
significantly correlated with median kep. Pathway analysis was
performed using GeneCodis with the KEGG database.
Setting the False Discovery Rate to 5% resulted in 1258 genes
that were significantly positively correlated with tumour leaki-
ness including integrins B1 and A6, TGFBR1, HIF1 and 2A, SMAD4,
HES1, JAG1. Interestingly, pathway analysis revealed that the p53
(P < 0.004), Wnt (P < 0.004) and Notch signalling pathways
(P < 0.006), which are known to have important roles in angiogen-
esis, were all significantly associated with tumour leakiness.
These results illustrate how the combination of non-invasive
imaging and gene expression profiling can reveal the molecular
correlates of radiological features and provide insight into the
mechanisms driving tumour growth and angiogenesis.
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Background: Lysosomal cathepsin proteases function in a pro-
grammed cell death (LPCD) pathway. Although there is evidence
for the importance of this pathway in cancer cell survival, it has
not been exploited in anti-cancer therapeutics. Hsp70 and ser-
pinB3 can block this pathway and promote cell survival. Further-
more, serpinB3 is associated with lack of response to
chemotherapy. Cathepsin mediated cell death is observed in
response to anthracyclines or taxanes, which are widely utilised
in breast cancer treatment.
Methods: We evaluated serpinB3 and Hsp70 by immunohisto-
chemistry in 255 surgically resected breast tumours from patients
treated with either CVAP or CVAP and docetaxel prior to poten-
tially curative resection. The study was performed with the
approval of the regional research ethics committee.
Results: SerpinB3 and Hsp70 were significantly correlated with
poor pathological response (P = 0.014 and P < 0.0001, respectively).
SerpinB3 positivity is a poor prognostic factor (P = 0.029; mean
survival 88.8 vs. 100.4 months) and this is independent in multi-
variate analysis (P = 0.023). Patients with serpinB3 positive
tumours have poor survival if treated with anthracycline
(P = 0.026) but not if they are also given a taxane (P = 0.786). Fur-
thermore, only patients with serpinB3 positive tumours benefit
from taxane treatment (P = 0.008).
Conclusions: SerpinB3 and Hsp70 are predictive biomarkers,
potentially blocking breast tumour response to chemotherapy
by preventing LPCD. SerpinB3 is prognostic and may prevent
anthracycline-, but not taxane-, mediated cytotoxicity in breast
tumours. Patients with serpinB3 negative tumours have a good
prognosis when treated with anthracycline-based therapy alone.
In contrast, patients with serpinB3 positive tumours benefit sig-
nificantly from the addition of docetaxel.
doi:10.1016/j.ejcsup.2010.06.036
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We have shown that insulin receptor substrate 1 (IRS-1) can
associate with epidermal growth factor receptor (EGFR), with acti-
vation of EGFR promoting recruitment and phosphorylation of
IRS-1 in an oestrogen receptor (ER)-positive tamoxifen resistant
breast cancer (BC) cell line. In this study, we examined recruit-
ment of IRS-1 by another erbB receptor family member, erbB3 in
three ER-positive BC cell lines. Our studies revealed an interaction
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